Scholarlink

<p>Biogenic silver nanoparticles (AgNPs) synthesized using aqueous extracts of <i>Pyracantha koidzumii</i> (AgNPs-P) and <i>Schinus molle</i> (AgNPs-S) were evaluated for antifungal activity against two clinical isolates (HCI-I and HCI-II) and an ATCC strain of <i>Candida albicans</i>. Synthesis was confirmed by UV–Vis, Fourier transform infrared spectrophotometry (FTIR), dynamic light scattering (DLS), electrophoretic light scattering (ELS), nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM) revealing stable, quasi-spherical particles averaging 15.13&#xa0;nm (AgNPs-P) and 10.81&#xa0;nm (AgNPs-S). Both types of AgNPs exhibited a minimum inhibitory concentration (MIC) of 1.56&#xa0;µg/mL across all strains. However, AgNPs-P demonstrated superior efficacy against HCI-I, with the lowest minimum fungistatic (6.25&#xa0;µg/mL) and fungicidal concentrations (12.5&#xa0;µg/mL). Notably, AgNPs-P eliminated fungal cells at a lower particle concentration (1.76 × 10<sup>10</sup> NPs/mL) yielding a lower particle efficiency index (2.8 × 10<sup>4</sup> NPs/CFU), underscoring their enhanced antifungal efficacy. Mechanistically, the AgNPs compromised cell wall integrity, inhibited hyphal growth, and reduced proteolytic activity. These results highlight the need to evaluate antifungal performance beyond MIC values and suggest AgNPs-P as a promising therapeutic candidate.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Within and Beyond the MIC: Unveiling the Antifungal Potency of Green-Synthesized Silver Nanoparticles Against Clinical Isolates of Candida albicans

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月13日

查看全文
  • Rodrigo Ramos-Hernández,
  • Francisco González-Díaz,
  • Enrique Salas-Téllez,
  • Monserrat Sordo,
  • Ana María Salazar,
  • Patricia Ostrosky-Wegman,
  • Miguel José Yacamán,
  • Abraham Méndez-Albores,
  • Alma Vázquez-Durán

摘要

Biogenic silver nanoparticles (AgNPs) synthesized using aqueous extracts of Pyracantha koidzumii (AgNPs-P) and Schinus molle (AgNPs-S) were evaluated for antifungal activity against two clinical isolates (HCI-I and HCI-II) and an ATCC strain of Candida albicans. Synthesis was confirmed by UV–Vis, Fourier transform infrared spectrophotometry (FTIR), dynamic light scattering (DLS), electrophoretic light scattering (ELS), nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM) revealing stable, quasi-spherical particles averaging 15.13 nm (AgNPs-P) and 10.81 nm (AgNPs-S). Both types of AgNPs exhibited a minimum inhibitory concentration (MIC) of 1.56 µg/mL across all strains. However, AgNPs-P demonstrated superior efficacy against HCI-I, with the lowest minimum fungistatic (6.25 µg/mL) and fungicidal concentrations (12.5 µg/mL). Notably, AgNPs-P eliminated fungal cells at a lower particle concentration (1.76 × 1010 NPs/mL) yielding a lower particle efficiency index (2.8 × 104 NPs/CFU), underscoring their enhanced antifungal efficacy. Mechanistically, the AgNPs compromised cell wall integrity, inhibited hyphal growth, and reduced proteolytic activity. These results highlight the need to evaluate antifungal performance beyond MIC values and suggest AgNPs-P as a promising therapeutic candidate.